The antisense pioneer has a big lead over its competitors in more ways than one.
Looking for cheap stocks that will pay you to own them? Here are three companies you might want to consider.
Let's look at the challenges and opportunities facing these Big Pharma stocks to see which is most attractive now.
The development-stage biotech may not have any earnings, but it's producing plenty of data to keep investors interested.
Inherent advantages in the healthcare system for drugmakers are fueling soaring drug prices.
A new collaboration with Amgen, Inc. is sparking investor optimism for a second consecutive day.
The biotech calendar is already chock-full of major catalysts in 2017. Here's a look at seven stocks that investors will definitely want to keep an eye on next year.
They're both promising names in the red-hot oncology space. But which stock is the better buy right now?
Achillion Pharmaceuticals, Ophthotech Corp., and Kite Pharmaceuticals shares could move wildly because of upcoming trial data.
Pfizer's acquisition of Anacor shows M&A is alive and well for biotech companies with late-stage research programs.